AstraZeneca Pushes PACIFIC-9 Monalizumab Readout to H1 2027 From H2 2026
IPHA sits 25% above its 52-week low of $1.17 on light trading volume (0.1× avg).
Summary
AstraZeneca moved the PACIFIC-9 Phase 3 readout for monalizumab to H1 2027 from H2 2026, citing the event-driven nature of the trial. Enrollment is complete, but the partnered milestone timeline slips by six to twelve months.
Key Events · Product Development and Regulatory · IPHA
-
PACIFIC-9 Readout Delayed to H1 2027
AstraZeneca now expects the high-level data readout for the PACIFIC-9 Phase 3 trial of durvalumab plus monalizumab or oleclumab in unresectable Stage III NSCLC in the first half of 2027, pushed from the second half of 2026 previously.
-
Enrollment Complete, Timing Event-Driven
Innate said the revision reflects the event-driven nature of the study and that enrollment in the trial is complete, so the delay is a timing issue rather than an enrollment or safety problem.
-
Partnered Milestone Cash Pushed Out
Monalizumab is developed under the 2015 co-development agreement with AstraZeneca, which took full oncology rights in October 2018; the readout is the gate for any further milestone payments from that program.
-
Funding Gap Widened by Delay
The H1 2026 report previously disclosed a €19.6M net loss, €21.4M of cash and negative equity of €40.5M, so a six-to-twelve-month slip in partnered milestone timing extends the period the company must fund itself.
Analysis · IPHA · Life Sciences
The only near-term value driver for monalizumab just slipped six to twelve months, and Innate gets no milestone cash from that program until the readout lands. Against a balance sheet that already showed €21.4M of cash and negative equity of €40.5M at the H1 2026 report, the delay widens the funding gap the August Sobi deal and September placement were meant to close. Enrollment is complete, so the trial itself is not at risk — this is an event-driven timing shift, not a safety or efficacy signal — but investors now wait until H1 2027 for the data that would trigger AstraZeneca milestones.
How filings like this one have moved
In the 30 days to Oct 27, 2026, 29.9% of the 1374 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.12%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IPHA was trading at $1.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $162.5M. The 52-week trading range was $1.17 to $2.71. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.